{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:51:39Z","timestamp":1791388299166,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.fjurol.2026.103156","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:46:56Z","timestamp":1782517616000},"page":"103156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC"],"prefix":"10.1016","volume":"36","author":[{"given":"Priscilla","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Long Depaquit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcq","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103156_bib0280","series-title":"Estimated number of new cases in 2020, worldwide, both sexes, all ages","author":"Cancer Today","year":"2021"},{"key":"10.1016\/j.fjurol.2026.103156_bib0285","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.fjurol.2024.102742","article-title":"Cancer Committee Guidelines\u00a0\u2013\u00a0update 2024\u20132026: non-muscle invasive bladder cancer (NMIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0290","doi-asserted-by":"crossref","first-page":"103011","DOI":"10.1016\/j.fjurol.2025.103011","article-title":"French recommendations of the AFU Oncology Committee for Bladder Cancer: update 2025","volume":"35","author":"Roumigui\u00e9","year":"2025","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0295","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u00a0\u2013\u00a02019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0300","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2009.06.009","article-title":"Traitement par instillations v\u00e9sicales de BCG et mitomycine C dans les tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: enqu\u00eate de pratique de l\u2019AFU aupr\u00e8s des urologues fran\u00e7ais","volume":"19","author":"Descazeaud","year":"2009","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0305","first-page":"1067","article-title":"Immunoth\u00e9rapie endov\u00e9sicale\u00a0: le bacille de Calmette-Gu\u00e9rin","volume":"11","author":"Chopin","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0310","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/jcm13133789","article-title":"Epirubicin and non-muscle invasive bladder cancer treatment: a systematic review","volume":"13","author":"Chiujdea","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.fjurol.2026.103156_bib0315","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.purol.2012.04.019","volume":"22","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0320","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"Recommandations du Comit\u00e9 de canc\u00e9rologie de l\u2019Association fran\u00e7aise d\u2019urologie (CC-AFU) pour la bonne pratique des instillations endov\u00e9sicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n\u2019envahissant pas le muscle (TVNIM)","volume":"22","author":"Roupr\u00eat","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0325","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.purol.2021.12.008","volume":"32","author":"Rollin","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0330","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.purol.2022.01.004","volume":"32","author":"Leon","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.purol.2022.01.001","volume":"32","author":"Audenet","year":"2022","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2026.103156_bib0340","doi-asserted-by":"crossref","first-page":"103105","DOI":"10.1016\/j.fjurol.2026.103105","article-title":"Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG","volume":"36","author":"Leon","year":"2026","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0345","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0350","series-title":"Recommandation de bonne pratique\u00a0: place de l\u2019ECBU avant une prise en charge urologique chirurgicale ou interventionnelle chez l\u2019adulte et modalit\u00e9s de traitement en cas de colonisation. Argumentaire complet","author":"CIAFU","year":"2026"},{"key":"10.1016\/j.fjurol.2026.103156_bib0355","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0360","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0365","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2010.12.002","article-title":"Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0370","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2026.103156_bib0375","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, MITOMYCINE MEDAC 40mg, poudre pour solution intrav\u00e9sicale. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69855350 (accessed October 16, 2021)."},{"issue":"5","key":"10.1016\/j.fjurol.2026.103156_bib0380","first-page":"CD006885","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fjurol.2026.103156_bib0385","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1586\/14737140.4.6.1057","article-title":"Advances in intravesical therapy of urinary bladder cancer","volume":"4","author":"Malmstrom","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.fjurol.2026.103156_bib0390","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, EPIRUBICINE ACCORD 2mg\/mL, solution injectable ou pour perfusion. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=68360453 (accessed October 16, 2021)."},{"key":"10.1016\/j.fjurol.2026.103156_bib0395","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit, BCG-MEDAC, poudre et solvant pour suspension intrav\u00e9sicale. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60973899 (accessed October 16, 2021)."},{"key":"10.1016\/j.fjurol.2026.103156_bib0400","series-title":"EMC\u00a0\u2013\u00a0Urologie","article-title":"Mode d\u2019action et principes d\u2019utilisation des instillations endov\u00e9sicales","author":"Leon","year":"2026"},{"key":"10.1016\/j.fjurol.2026.103156_bib0405","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bju.15413","article-title":"Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu\u00e9rin induction does not impact therapeutic response","volume":"128","author":"Hensley","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103156_bib0410","doi-asserted-by":"crossref","first-page":"e8300","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Gu\u00e9rin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.fjurol.2026.103156_bib0415","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0420","doi-asserted-by":"crossref","first-page":"e14377","DOI":"10.1111\/ctr.14377","article-title":"The safety and efficacy of Bacillus Calmette-Gu\u00e9rin intravesical therapy in kidney transplant recipients with superficial bladder cancer","volume":"35","author":"Alkassis","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.fjurol.2026.103156_bib0425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-020-00642-1","article-title":"Can we treat bladder cancer with intravesical Bacillus Calmette-Gu\u00e9rin in patients with prior tuberculosis infection? A population-based cohort study","volume":"20","author":"Hsu","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0430","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Gu\u00e9rin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0435","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.purol.2020.04.028","volume":"31","author":"Boissier","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0440","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2026.103156_bib0445","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103156_bib0450","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0455","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/sur.2024.119","article-title":"Is there always a need to perform urine culture before bacillus Calmette-Gu\u00e9rin instillation for bladder cancer?","volume":"26","author":"Bourgi","year":"2025","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.fjurol.2026.103156_bib0460","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder cancer and asymptomatic bacteriuria","volume":"187","author":"Herr","year":"2012","journal-title":"J Urol"},{"issue":"11 Pt B","key":"10.1016\/j.fjurol.2026.103156_bib0465","first-page":"E658","article-title":"Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria","volume":"110","author":"Herr","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103156_bib0470","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2012.08.013","article-title":"Intravesical bacille Calmette-Gu\u00e9rin eradicates bacteriuria in antibiotic-na\u00efve bladder cancer patients","volume":"63","author":"Herr","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0475","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.aju.2016.03.002","article-title":"Cystoscopy and intravesical bacille Calmette-Gu\u00e9rin therapy in antibiotic-na\u00efve patients with bladder cancer with asymptomatic bacteriuria: an update","volume":"14","author":"Herr","year":"2016","journal-title":"Arab J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0480","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/iju.14139","article-title":"Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Gu\u00e9rin?","volume":"27","author":"Herr","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.urology.2018.10.023","article-title":"Reduced recurrence of low-grade papillary bladder tumors associated with asymptomatic bacteriuria","volume":"124","author":"Herr","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2026.103156_bib0490","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.fjurol.2026.103156_bib0495","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000477673","article-title":"Safety and efficacy of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review","volume":"99","author":"Poletajew","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.fjurol.2026.103156_bib0505","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103156_bib0510","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Gu\u00e9rin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0515","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01302-08","article-title":"Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics","volume":"53","author":"Ritz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.fjurol.2026.103156_bib0520","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0525","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0530","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3760\/cma.j.issn.0366-6999.20141045","article-title":"Reduced dose of Bacillus Calmette-Gu\u00e9rin versus full dose of Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer after transurethral resection bladder tumor: a meta-analysis of randomized controlled trials","volume":"127","author":"Qin","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.fjurol.2026.103156_bib0535","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0540","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0545","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103156_bib0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:59:34Z","timestamp":1791385174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2950393026000872"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103156","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103156"}}